Together with the findings by Cui et al., this suggests that targeting galectin-3 could be beneficial for ESCC patients as it has direct effects on the tumor cells and sensitizes the cells for combination treatment. The gene discussed is LGALS3; the disease is esophageal squamous cell carcinoma.